On a deal spree, Takeda grabs Japanese cabo rights in $145M pact with Exelixis
A deal-hungry Takeda has stepped up with a $145 million pact to partner with Exelixis on cabozantinib.
Exelixis $EXEL grabbed a $50 million upfront …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
